ARIES FUND MANAGEMENT LIMITED

Financial Health Score: B-

Explanation: The patient possesses a robust constitution thanks to a substantial historical accumulation of wealth (over £12.6 million in net assets) and healthy liquidity. However, the score is pulled down by concerning symptoms of chronic bleeding in the form of consecutive years of declining retained earnings, alongside a sudden, acute swelling in short-term creditors and stock holdings. While not currently in critical condition, the underlying business is experiencing sustained stress that requires diagnostic attention.

Key Vital Signs

• Net Assets / Shareholders' Funds: £12,666,197
  • Interpretation: This is the company's core "muscle mass." At over £12.6 million, the company is strongly capitalized and has a significant equity buffer. However, this is down from £15.7 million just two years ago, indicating that the patient has been losing weight.
• Current Ratio (Liquidity): ~4.6 to 1
  • Interpretation: With £16 million in current assets against £3.46 million in current liabilities, the company has excellent short-term liquidity. The "blood flow" is sufficient to meet all immediate obligations, with plenty of room to maneuver.
• Cash Reserves: £1,031,299
  • Interpretation: A healthy pulse. Cash has improved from £581k in 2024 and £527k in 2023, showing that the company is generating or retaining liquid funds despite overall equity declines.
• Stocks (Inventory): £10,690,396
  • Interpretation: A massive swelling. Stocks have nearly doubled from £5.8 million in 2024 to £10.6 million in 2025. Given the nature of the business (SIC 82990 / trading financial instruments), this likely represents securities or financial instruments held for resale. This concentration in stock represents a significant portion of current assets and is highly susceptible to market volatility.
• Current Liabilities: £3,463,361
  • Interpretation: A sudden spike in "short-term debt load." Liabilities jumped tenfold from £346k in 2024 to £3.46 million in 2025, driven almost entirely by "Other Creditors" (£3.46 million). This coincides directly with the increase in stock, suggesting the company has taken on short-term obligations to fund its enlarged trading portfolio.

Diagnosis

Condition: Stable but deteriorating, with acute localized swelling.

The financial data reveals a business that is structurally sound but operationally underperforming. The most alarming symptom is the chronic bleeding of retained earnings. Over the last two financial years, the Profit and Loss reserve has dropped from £15.78 million to £12.66 million—a loss of over £3 million in equity. Because the income statement is exempt from filing, we cannot see the exact revenue or expense lines, but this erosion strongly suggests either trading losses or significant fair value write-downs on their financial instruments.

The most striking feature of the 2025 balance sheet is the acute swelling in both Stocks and Creditors. The company has essentially leveraged itself in the short term, taking on approximately £3.46 million in creditors to fund a near-doubling of its stock (trading portfolio). While the current ratio remains healthy, this represents a significant shift in risk profile. The patient is carrying much more volatile "weight" (stock) funded by short-term "stress" (creditors).

Furthermore, the presence of a USD 7,000,000 multi-option facility with UBS secured by a deed of charge indicates that the company has access to substantial external leverage, making the risk of margin calls or forced asset sales a relevant concern if the market turns against their stock positions.

Recommendations

1. Investigate the Source of the Bleeding: Conduct an internal review to determine the exact cause of the £3 million decline in P&L reserves over the past two years. Distinguish between realized trading losses and unrealized fair value adjustments. If the core trading strategy is unprofitable, a change in strategy is required to stop the hemorrhage.
2. Monitor the Leverage Swelling: Keep a very close eye on the relationship between the £3.46 million in creditors and the £10.6 million in stocks. Ensure that the stock can be liquidated at sufficient value to clear the short-term creditor obligations.
3. Stress-Test the Portfolio: Given the heavy concentration in stocks/financial instruments and the UBS facility, run scenario analyses to ensure the company can meet margin calls or creditor demands if market liquidity dries up or asset prices fall.
4. Maintain Cash Reserves: Do not let the healthy cash position of £1 million drop. This cash acts as a vital "immunization" against sudden market shocks or unexpected demands from the UBS facility.